ETOPOSIDE
Pancreatic Cancer Metastatic
Jin XuSmall moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
26 Active assets in the Pancreatic Cancer Metastatic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ivospemin Panbela Therapeutics, Inc. | Phase 2/3 | B |
Retifanlimab Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | B |
Adebrelimab West China Hospital | Phase 2 | B |
Zoldonrasib Revolution Medicines, Inc. | Phase 3 | B |
Mgnp Immuneering Corporation | Phase 3 | B |
View all 27 →
Same molecule, other indications
ETOPOSIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →